{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:53:11Z","timestamp":1781131991735,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["Cooperative Studies Program"],"award-info":[{"award-number":["Cooperative Studies Program"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To address the US opioid epidemic, there is an urgent clinical need to provide persons with opioid use disorder (OUD) with effective medication treatments for OUD (MOUD). Formulations of sublingual buprenorphine\/naloxone (SL-BUP\/NLX) are considered the standard of care for OUD including within the Veterans Healthcare Administration (VHA). However, poor retention on MOUD undermines its effectiveness. Long-acting injectable monthly buprenorphine (INJ-BUP) (e.g., Sublocade\u00ae) has the potential to improve retention and therefore reduce opioid use and overdose. Designing and conducting studies for OUD pose unique challenges. The strategies and solutions to some of these considerations in designing Cooperative Studies Program (CSP) 2014, Buprenorphine for Treating Opioid Use Disorder in Veterans (VA<jats:bold>-<\/jats:bold>BRAVE), a randomized, 20-site, clinical effectiveness trial comparing INJ-BUP to SL-BUP\/NLX conducted within the VHA may provide valuable guidance for others confronted with similar investigation challenges.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This 52-week, parallel group, open-label, randomized controlled trial (RCT) evaluates the comparative effectiveness of two current FDA-approved formulations of buprenorphine: (1) daily SL-BUP\/NLX vs. (2) monthly (28-day) INJ-BUP for Veterans with moderate to severe OUD (n\u2009=\u2009952)<jats:bold>.<\/jats:bold> The primary outcomes are (1) retention in MOUD and (2) opioid abstinence. Secondary outcomes include measures of other drug use, psychiatric symptoms, medical outcomes including prevalence rates of HIV, hepatitis B and C as well as social outcomes (housing instability, criminal justice involvement), service utilization and cost-effectiveness. Special considerations in conducting a comparative effectiveness trial with this population and during COVID-19 pandemic were also included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The evaluation of the extended-release formulation of buprenorphine compared to the standard sublingual formulation in real-world VHA settings is of paramount importance in addressing the opioid epidemic. The extent to which this new treatment facilitates retention, decreases opioid use, and prevents severe sequelae of OUD has not been studied in any long-term trial to date. Positive findings in this trial could lead to widespread adoption of MOUD, and, if proven superior INJ-BUP, by clinicians throughout the VHA and beyond. This treatment has the potential to reduce opioid use among Veterans, improve medical, psychological, and social outcomes, and save lives at justifiable cost.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Registered at Clinicaltrials.gov NCT04375033<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00286-6","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T13:03:13Z","timestamp":1643634193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans"],"prefix":"10.1186","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct04375033","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6894-5946","authenticated-orcid":false,"given":"Ismene","family":"Petrakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ralevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hermos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melynn","family":"Nuite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rosenheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"286_CR1","doi-asserted-by":"publisher","first-page":"897","DOI":"10.15585\/mmwr.mm6634a2","volume":"66","author":"JK O'Donnell","year":"2017","unstructured":"O\u2019Donnell JK, Gladden RM, Seth P. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region\u2014United States, 2006\u20132015. MMWR Morb Mortal Wkly Rep. 2017;66:897\u2013903. https:\/\/doi.org\/10.15585\/mmwr.mm6634a2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"286_CR2","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1001\/jama.2015.11859","volume":"314","author":"B Han","year":"2015","unstructured":"Han B, Compton WM, Jones CM, et al. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003\u20132013. JAMA. 2015;314:1468\u201378. https:\/\/doi.org\/10.1001\/jama.2015.11859.","journal-title":"JAMA"},{"key":"286_CR3","unstructured":"Hedegaard H, Warner M, Mini\u00f1o AM. Drug overdose deaths in the United States, 1999\u20132016. NCHS Data Brief. 2017:1\u20138."},{"key":"286_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.amepre.2019.01.016","volume":"57","author":"L Lin","year":"2019","unstructured":"Lin L, Peltzman T, McCarthy JF, et al. Changing trends in opioid overdose deaths and prescription opioid receipt among veterans. Am J Prev Med. 2019;57:106\u201310. https:\/\/doi.org\/10.1016\/j.amepre.2019.01.016.","journal-title":"Am J Prev Med"},{"key":"286_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2018.1452327","author":"JJ Wyse","year":"2018","unstructured":"Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the department of veterans affairs (VA) health care system: historical perspective, lessons learned and next steps. Subst Abus. 2018. https:\/\/doi.org\/10.1080\/08897077.2018.1452327.","journal-title":"Subst Abus"},{"key":"286_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamainternmed.2017.0147","volume":"177","author":"WF Gellad","year":"2017","unstructured":"Gellad WF, Good CB, Shulkin DJ. Addressing the opioid epidemic in the United States: lessons from the department of veterans affairs. JAMA Internal Med. 2017;177:611\u20132. https:\/\/doi.org\/10.1001\/jamainternmed.2017.0147.","journal-title":"JAMA Internal Med"},{"key":"286_CR7","volume-title":"Provisional drug overdose death counts","author":"F Ahmad","year":"2020","unstructured":"Ahmad F, Escobedo L, Rossen L, et al. Provisional drug overdose death counts. Hyattsville: National Center for Health Statistics; 2020."},{"key":"286_CR8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","volume":"69","author":"N Wilson","year":"2020","unstructured":"Wilson N, Kariisa M, Seth P, et al. Drug and opioid-involved overdose deaths\u2014United States, 2017\u20132018. MMWR Morb Mortal Wkly Rep. 2020;69:290\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm6911a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"286_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.18543","author":"DF Haley","year":"2020","unstructured":"Haley DF, Saitz R. The opioid epidemic during the COVID-19 pandemic. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.18543.","journal-title":"JAMA"},{"key":"286_CR10","volume-title":"SAMHSA\/HHS: an update on the opioid crisis","author":"E McCance-Katz","year":"2018","unstructured":"McCance-Katz E. SAMHSA\/HHS: an update on the opioid crisis. Rockville: SAMHSA; 2018."},{"key":"286_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/08897077.2020.1787299","volume":"41","author":"AJ Gordon","year":"2020","unstructured":"Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped care for opioid use disorder train the trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abus. 2020;41:275\u201382. https:\/\/doi.org\/10.1080\/08897077.2020.1787299.","journal-title":"Subst Abus"},{"key":"286_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5055\/jom.2018.0447","volume":"14","author":"T Iheanacho","year":"2018","unstructured":"Iheanacho T, Stefanovics E, Rosenheck R. Opioid use disorder and homelessness in the Veterans Health Administration: the challenge of multimorbidity. J Opioid Manag. 2018;14:171\u201382. https:\/\/doi.org\/10.5055\/jom.2018.0447.","journal-title":"J Opioid Manag"},{"key":"286_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJMra1604339","volume":"375","author":"MA Schuckit","year":"2016","unstructured":"Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375:357\u201368. https:\/\/doi.org\/10.1056\/NEJMra1604339.","journal-title":"N Engl J Med"},{"key":"286_CR14","volume-title":"Buprenorphine","author":"SAMSHSA","year":"2018","unstructured":"SAMSHSA. Buprenorphine. Substance Abuse and Mental Health Services Administration: Rockville; 2018."},{"key":"286_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","volume":"28","author":"L Amato","year":"2005","unstructured":"Amato L, Davoli M, Perucci CA, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28:321\u20139. https:\/\/doi.org\/10.1016\/j.jsat.2005.02.007.","journal-title":"J Subst Abuse Treat"},{"key":"286_CR16","unstructured":"Global Commission on Drug Policy. Taking control: pathways to drug policies that work. https:\/\/www.globalcommissionondrugs.org\/reports\/taking-control-pathways-to-drug-policies-that-work (2014)."},{"key":"286_CR17","volume-title":"WHO\/UNODC\/UNAIDS position paper: substitution maintenance therapy in the management of opioid dependence and HIV\/AIDS prevention","author":"World Health Organization","year":"2004","unstructured":"World Health Organization. WHO\/UNODC\/UNAIDS position paper: substitution maintenance therapy in the management of opioid dependence and HIV\/AIDS prevention. Geneva: World Health Organization, United Nations Office on Drugs and Crimes, UNAIDS; 2004."},{"key":"286_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s0740-5472(03)00029-1","volume":"24","author":"KH Wong","year":"2003","unstructured":"Wong KH, Lee SS, Lim WL, et al. Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abus Treat. 2003;24:233\u20139. https:\/\/doi.org\/10.1016\/s0740-5472(03)00029-1.","journal-title":"J Subst Abus Treat"},{"key":"286_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35:22\u201335. https:\/\/doi.org\/10.1080\/10550887.2016.1100960.","journal-title":"J Addict Dis"},{"key":"286_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","volume":"85","author":"JR Morgan","year":"2018","unstructured":"Morgan JR, Schackman BR, Leff JA, et al. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abus Treat. 2018;85:90\u20136. https:\/\/doi.org\/10.1016\/j.jsat.2017.07.001.","journal-title":"J Subst Abus Treat"},{"key":"286_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O'Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, et al. Retention of patients in opioid substitution treatment: a systematic review. PLoS ONE. 2020;15: e0232086. https:\/\/doi.org\/10.1371\/journal.pone.0232086.","journal-title":"PLoS ONE"},{"key":"286_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ajad.12553","volume":"26","author":"A Manhapra","year":"2017","unstructured":"Manhapra A, Petrakis I, Rosenheck R. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. Am J Addict. 2017;26:572\u201380. https:\/\/doi.org\/10.1111\/ajad.12553.","journal-title":"Am J Addict"},{"key":"286_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3109\/00952999209026068","volume":"18","author":"JF Maddux","year":"1992","unstructured":"Maddux JF, Desmond DP. Ten-year follow-up after admission to methadone maintenance. Am J Drug Alcohol Abus. 1992;18:289\u2013303.","journal-title":"Am J Drug Alcohol Abus"},{"key":"286_CR24","doi-asserted-by":"crossref","unstructured":"Stimmel B, Goldberg J, Rotkopf E, et al. Ability to remain abstinent after methadone detoxification. A six-year study. JAMA 1977; 237: 1216\u20131220. 1977\/03\/21.","DOI":"10.1001\/jama.237.12.1216"},{"key":"286_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1947","volume":"357","author":"A Manhapra","year":"2017","unstructured":"Manhapra A, Rosenheck R, Fiellin DA. Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. BMJ. 2017;357: j1947. https:\/\/doi.org\/10.1136\/bmj.j1947.","journal-title":"BMJ"},{"key":"286_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jsat.2012.03.008","volume":"43","author":"R Schwarz","year":"2012","unstructured":"Schwarz R, Zelenev A, Bruce RD, et al. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abus Treat. 2012;43:451\u20137. https:\/\/doi.org\/10.1016\/j.jsat.2012.03.008.","journal-title":"J Subst Abus Treat"},{"key":"286_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s11524-010-9438-4","volume":"87","author":"SA Springer","year":"2010","unstructured":"Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health. 2010;87:592\u2013602. https:\/\/doi.org\/10.1007\/s11524-010-9438-4.","journal-title":"J Urban Health"},{"key":"286_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038335","volume":"7","author":"SA Springer","year":"2012","unstructured":"Springer SA, Qiu J, Saber-Tehrani AS, et al. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS ONE. 2012;7: e38335. https:\/\/doi.org\/10.1371\/journal.pone.0038335.","journal-title":"PLoS ONE"},{"key":"286_CR29","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/s0140-6736(18)32259-1","volume":"393","author":"BR Haight","year":"2019","unstructured":"Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393:778\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(18)32259-1.","journal-title":"Lancet"},{"key":"286_CR30","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1016\/j.nurpra.2020.06.028","volume":"16","author":"J Rioux","year":"2020","unstructured":"Rioux J, Cuellar N, Oliver J, et al. Evaluating retention rates in a medication-assisted treatment program. J Nurse Pract. 2020;16:e149\u201351. https:\/\/doi.org\/10.1016\/j.nurpra.2020.06.028.","journal-title":"J Nurse Pract"},{"key":"286_CR31","volume-title":"Diagnostic and statistical manual of mental disorders","author":"APA","year":"2013","unstructured":"APA. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C: American Psychiatric Association; 2013.","edition":"5"},{"key":"286_CR32","first-page":"1","volume":"14","author":"ASAM","year":"2020","unstructured":"ASAM. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update: Erratum. J Addict Med. 2020;14:1\u201391.","journal-title":"J Addict Med"},{"key":"286_CR33","unstructured":"The Management of Substance Abuse Use Disorders Working Group. In: The Office of Quality and Safety VA Washington DC and Quality Management Division United States Army MEDCOM, editors. VA\/DoD clinical practice guidelines for management of substance use disorders (SUD). 2015; Washington DC. p. 1\u2013169."},{"key":"286_CR34","unstructured":"SAMHSA SAaMHSA. Medications for opioid use disorder. In: Administration SAaMHS, editor. Treatment improvement protocol (TIP) series 63. Rockville: Substance Abuse and Mental Health Services Administration; 2018."},{"key":"286_CR35","unstructured":"Slough I. INDIVIOR PLC results from the phase 3 pivotal study of RBP-6000 buprenorphine monthly depot for the treatment of opioid use disorder. In: Conference on problem of drug dependence (CPDD). Montreal, Canada; 2017."},{"key":"286_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0376-8716(96)01263-X","volume":"42","author":"LC Sobell","year":"1996","unstructured":"Sobell LC, Brown J, Leo GI, et al. The reliability of the alcohol timeline followback when administered by telephone and by computer. Drug Alcohol Depend. 1996;42:49\u201354.","journal-title":"Drug Alcohol Depend"},{"key":"286_CR37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/ajad.13051","volume":"29","author":"BE Biondi","year":"2020","unstructured":"Biondi BE, Zheng X, Frank CA, et al. A literature review examining primary outcomes of medication treatment studies for opioid use disorder: what outcome should be used to measure opioid treatment success? Am J Addict. 2020;29:249\u201367. https:\/\/doi.org\/10.1111\/ajad.13051.","journal-title":"Am J Addict"},{"key":"286_CR38","unstructured":"Veterans Administration. VA MISSION Act. https:\/\/missionact.va.gov\/. (2020)."},{"issue":"Suppl 20","key":"286_CR39","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333 (quiz 34\u201357).","journal-title":"J Clin Psychiatry"},{"key":"286_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","volume":"35","author":"DR Wesson","year":"2003","unstructured":"Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoact Drugs. 2003;35:253\u20139.","journal-title":"J Psychoact Drugs"},{"key":"286_CR41","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","volume":"84","author":"J Sullivan","year":"1989","unstructured":"Sullivan J, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84:1353\u20137.","journal-title":"Br J Addict"},{"key":"286_CR42","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606\u201313.","journal-title":"J Gen Intern Med"},{"key":"286_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring alcohol consumption: psychosoical and biological methods","author":"LC Sobell","year":"1992","unstructured":"Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen J, editors. Measuring alcohol consumption: psychosoical and biological methods. Totowa: Humana Press; 1992. p. 41\u201372."},{"key":"286_CR44","doi-asserted-by":"publisher","first-page":"423","DOI":"10.15288\/jsa.1995.56.423","volume":"56","author":"MJ Bohn","year":"1995","unstructured":"Bohn MJ, Babor TF, Kranzler HR. The alcohol use disorders identification test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56:423\u201332.","journal-title":"J Stud Alcohol"},{"key":"286_CR45","volume-title":"Columbia-suicide severity rating scale (C-SSRS)","author":"K Posner","year":"2008","unstructured":"Posner K, Brent D, Lucas C, et al. Columbia-suicide severity rating scale (C-SSRS). New York: Columbia Univeristy Medical Center; 2008."},{"key":"286_CR46","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.cct.2004.05.001","volume":"25","author":"EZ Oddone","year":"2004","unstructured":"Oddone EZ, Olsen MK, Lindquist JH, et al. Enrollment in clinical trials according to patients race: experience from the VA cooperative studies program (1975\u20132000). Control Clin Trials. 2004;25:378\u201387. https:\/\/doi.org\/10.1016\/j.cct.2004.05.001.","journal-title":"Control Clin Trials"},{"key":"286_CR47","volume-title":"Fact sheet: President Obama proposes $1.1 billion in new funding to address the prescription opioid abuse and heroin use epidemic","author":"The White House","year":"2016","unstructured":"The White House. Fact sheet: President Obama proposes $1.1 billion in new funding to address the prescription opioid abuse and heroin use epidemic. Washington, D.C: The White House; 2016."},{"key":"286_CR48","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","volume":"178","author":"MR Lofwall","year":"2018","unstructured":"Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Internal Med. 2018;178:764\u201373. https:\/\/doi.org\/10.1001\/jamainternmed.2018.1052.","journal-title":"JAMA Internal Med"},{"key":"286_CR49","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/add.14636","volume":"114","author":"M Frost","year":"2019","unstructured":"Frost M, Bailey GL, Lintzeris N, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction. 2019;114:1416\u201326. https:\/\/doi.org\/10.1111\/add.14636.","journal-title":"Addiction"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00286-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00286-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00286-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T13:30:29Z","timestamp":1643635829000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00286-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00286-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is approved by the VA-Central Institutional Review Board (CIRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors S. Springer and I. Petrakis have received consultation honoraria and have received study drug donated in-kind from Alkermes Inc; Author S. Springer has received study drug donated in-kind from Indivior Inc. for a NIDA-funded study. TR Kosten has received consultation honoraria from Alkermes Inc. Author A. Saxon received consultation honorarium from Indivior, Inc., received consultation honorarium and travel support from Alkermes, Inc., and royalties from UpToDate, Inc. Author Adam J. Gordon receive royalties from UpToDate, Inc., for an online chapter unrelated to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}